Tracleer (bosentan) may be of significant benefit to people with borderline or less severe pulmonary hypertension due to idiopathic pulmonary fibrosis, results from an ongoing clinical trial suggest.

According to interim data collected from the Japanese study, Tracleer — an approved therapy for pulmonary arterial hypertension (PAH) — significantly improved the prognosis of treated IPF-PH patients and and their capacity to perform daily life activities, without a worsening in pulmonary function.

Preliminary data from the long-term trial (UMIN000004749), still recruiting in Japan and expected to run through 2022, were recently released.